GlobeNewswire

Jushi Holdings Inc. Announces Receipt of DEA Registrations for State-Licensed Medical Cannabis Operations
03/11/2026
BOCA RATON, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) ( OTCQX: JUSH ), a vertically integrated, multi-state cannabis operator, today announced that it has [...]
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
03/11/2026
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approved [...]
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
03/11/2026
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) [...]
Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
03/11/2026
AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter Continued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 [...]
Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update
03/11/2026
Q3 2026 total product revenue of $125.5 million , reflecting 19% growth year-over-year IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million Strong financial position with $285.3 million in cash, cash [...]
Xenon to Present at Upcoming Investor Conferences
03/11/2026
VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
03/11/2026
BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi [...]
Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/11/2026
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of [...]
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
03/11/2026
Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
03/11/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address [...]
Aura Biosciences to Participate in Upcoming Investor Conference
03/11/2026
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, [...]
Globus Medical Acquires Synaptive Medical, Strengthening Its Position in Cranial Neurosurgery
03/11/2026
AUDUBON, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. a leading musculoskeletal technology company, today announced that it completed the acquisition of Synaptive Medical, deepening the Company's presence [...]
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
03/11/2026
Alamar’s NULISAseq™ Immune 340 and NULISAseq™ Neuro 220 panels will be used to investigate disease progression, biological subtypes and treatment response FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar [...]
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
03/11/2026
Licaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated around year-end 2026 [...]
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
03/11/2026
ROCKVILLE, MD, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, [...]
Amwell® Announces Results for the Third Quarter 2026
03/11/2026
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended [...]
Mobia Medical to Participate in the 8th Annual Wolfe Research Healthcare Conference
03/11/2026
AUSTIN, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that [...]
Inspire Medical Systems, Inc. to Present at the Stifel 2026 Healthcare Conference
03/11/2026
MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
03/11/2026
RADNOR, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum